WO2005095973A3 - Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) - Google Patents

Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) Download PDF

Info

Publication number
WO2005095973A3
WO2005095973A3 PCT/EP2005/002595 EP2005002595W WO2005095973A3 WO 2005095973 A3 WO2005095973 A3 WO 2005095973A3 EP 2005002595 W EP2005002595 W EP 2005002595W WO 2005095973 A3 WO2005095973 A3 WO 2005095973A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
gpr54
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/002595
Other languages
French (fr)
Other versions
WO2005095973A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005095973A2 publication Critical patent/WO2005095973A2/en
Publication of WO2005095973A3 publication Critical patent/WO2005095973A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human GPR54 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cancer disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cancer disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR54 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/002595 2004-03-25 2005-03-11 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) WO2005095973A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007163.1 2004-03-25
EP04007163 2004-03-25

Publications (2)

Publication Number Publication Date
WO2005095973A2 WO2005095973A2 (en) 2005-10-13
WO2005095973A3 true WO2005095973A3 (en) 2005-12-08

Family

ID=34963167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002595 WO2005095973A2 (en) 2004-03-25 2005-03-11 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)

Country Status (1)

Country Link
WO (1) WO2005095973A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (en) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2004080479A1 (en) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited Gonadal function improving agents
NZ552029A (en) 2004-06-25 2009-01-31 Takeda Pharmaceutical Metastin derivatives and use thereof
TWI386417B (en) 2005-12-22 2013-02-21 Takeda Pharmaceutical Metastin derivatives and use thereof
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (en) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co Metastin Derivatives And Use Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042486A1 (en) * 1999-12-08 2001-06-14 Smithkline Beecham Corporation Axor12
US20020106766A1 (en) * 2000-08-16 2002-08-08 Nabil Elshourbagy Molecular cloning of a galanine-like 7 transmembrane receptor (AXOR12 RAT)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042486A1 (en) * 1999-12-08 2001-06-14 Smithkline Beecham Corporation Axor12
US20020106766A1 (en) * 2000-08-16 2002-08-08 Nabil Elshourbagy Molecular cloning of a galanine-like 7 transmembrane receptor (AXOR12 RAT)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARMS J F ET AL: "KISS1 metastasis suppression and emergent pathways", CLINICAL & EXPERIMENTAL METASTASIS, vol. 20, no. 1, January 2003 (2003-01-01), pages 11 - 18, XP002303011, ISSN: 0262-0898 *
IKEGUCHI MASAHIDE ET AL: "Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocellular carcinoma.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 129, no. 9, September 2003 (2003-09-01), pages 531 - 535, XP009050044, ISSN: 0171-5216 *
MASUI T ET AL: "Metastin and its variant forms suppress migration of pancreatic cancer cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 315, no. 1, 27 February 2004 (2004-02-27), pages 85 - 92, XP004487244, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2005095973A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005106488A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2005093425A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase